Effect of Narrow-Band Ultraviolet B Phototherapy and Methotrexate on MicroRNA (146a) Levels in Blood of Psoriatic Patients

Ele-Refaei, Asmaa M.; Elesawy, Fatma Mohamed

doi:10.1155/2015/145769

Cited by 16 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-10a, miR-132-3p, miR-146a-5p, and miR-155-5p measured in whole blood or serum have been shown to be increased after MTX treatment in RA [33, 34] whereas miR-16 in plasma was not altered by the use of MTX in juvenile idiopathic arthritis [35]. In contrast, miR-146a measured in whole blood from patients with psoriasis was decreased after 3 months of methotrexate [36]. Also, in psoriasis, miR-223-3p was found downregulated in PBMC, but not altered in serum after the use of MTX and decreased in serum of patients treated by Etanercept [37, 38].…”

Section: Discussionmentioning

confidence: 99%

Deregulation of microRNA expression in monocytes and CD4+ T lymphocytes from patients with axial spondyloarthritis

et al. 2019

View full text Add to dashboard Cite

BackgroundMicroRNAs (MiRs) play an important role in the pathogenesis of chronic inflammatory diseases. This study is the first to investigate miR expression profiles in purified CD4+ T lymphocytes and CD14+ monocytes from patients with axial spondyloarthritis (axSpA) using a high-throughput qPCR approach.MethodsA total of 81 axSpA patients fulfilling the 2009 ASAS classification criteria, and 55 controls were recruited from October 2014 to July 2017. CD14+ monocytes and CD4+ T lymphocytes were isolated from peripheral blood mononuclear cells. MiR expression was investigated by qPCR using the Exiqon Human MiRnome panel I analyzing 372 miRNAs. Differentially expressed miRNAs identified in the discovery cohort were validated in the replication cohort.ResultsWe found a major difference in miR expression patterns between T lymphocytes and monocytes regardless of the patient or control status. Comparing disease-specific differentially expressed miRs, 13 miRs were found consistently deregulated in CD14+ cells in both cohorts with miR-361-3p, miR-223-3p, miR-484, and miR-16-5p being the most differentially expressed. In CD4+ T cells, 11 miRs were differentially expressed between patients and controls with miR-16-1-3p, miR-28-5p, miR-199a-5p, and miR-126-3p were the most strongly upregulated miRs among patients. These miRs are involved in disease relevant pathways such as inflammation, intestinal permeability or bone formation. Mir-146a-5p levels correlated inversely with the degree of inflammation in axSpA patients.ConclusionsWe demonstrate a consistent deregulation of miRs in both monocytes and CD4+ T cells from axSpA patients, which could contribute to the pathophysiology of the disease with potential interest from a therapeutic perspective.Electronic supplementary materialThe online version of this article (10.1186/s13075-019-1829-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Deregulation of microRNA expression in monocytes and CD4+ T lymphocytes from patients with axial spondyloarthritis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In an Egyptian cohort, patients with psoriasis had abnormally higher miR-146a expression, and MTX treatment significantly reduced miR-146a expression [ 28 ]. Over 96% of PsA patients in our study received MTX that resulted in a significant decrease in CRP levels (CRP monitored at inclusion versus after 6 months) after treatment ( p = 0.0011) (Table 1 ).…”

Section: Discussionmentioning

confidence: 99%

MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis

et al. 2018

View full text Add to dashboard Cite

BackgroundPsoriasis and psoriatic arthritis (PsA) are inflammatory associated autoimmune disorders. MicroRNA (miR)-146a plays a crucial role in regulating inflammation. A single nucleotide polymorphism in the miR-146a gene (rs2910164), aberrantly alters its gene expression and linked with the pathogenesis of several disorders, including psoriasis and PsA. In South Africa, psoriasis and PsA are extremely rare in the indigenous African population and most common in both the Indian and Caucasian population. The aim of this study was to investigate whether the miR-146a rs2910164 contributes towards psoriasis and PsA development in South African Indian and Caucasian patients.MethodsSouth African Indian (n = 84) and Caucasian (n = 32) PsA patients (total n = 116) and healthy control subjects (Indian: n = 62 and Caucasian: n = 38; total n = 100) were recruited in the study. DNA was extracted from whole blood taken from all subjects, and genotyped for the miR-146a rs2910164 using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Data for laboratory parameters were obtained from pathology reports. The consulting rheumatologist collected all other clinical data.ResultsUnstratified data (Caucasians + Indians): A significant decrease in C-reactive protein (CRP) levels in PsA patients was observed (CRP monitored at inclusion vs. after 6 months of treatment) (18.95 ± 2.81 mg/L vs. 9.68 ± 1.32 mg/L, p = 0.0011). The miR-146a rs2910164 variant C-allele frequency in PsA patients was significantly higher vs. healthy controls (35.78% vs. 26% respectively, p = 0.0295, OR = 1.59 95% CI 1.05–2.40). Stratified data (Indians): The variant C-allele frequency in Indian PsA patients was significantly higher vs. healthy Indian controls (35.71% vs. 22.58%, p = 0.0200, OR = 1.91 95% CI 1.13–3.22). Stratified data (Caucasians): The variant C-allele frequency distribution between Caucasian PsA patients and healthy Caucasian controls was similar.ConclusionThe rs2910164 variant C-allele may play a role in the progression of PsA in the South African Indian population. The main limitation in this study was the small sample size in the case-control cohorts, with a low overall statistical power (post-hoc power analysis = 19%).

show abstract

“…For example, examinations of dysregulated miRNAs in response to treatment with UV-A and 8-methoxypsoralen (so-called PUVA therapy) revealed that miR-4516 is upregulated, which contributes to decreased expression of UBE2N, STAT3, and CDK6 proteins, resulting in apoptosis [ 54 , 55 ]. Similarly, two reports observed the dysregulation of miR-21, miR-125b, miR-146a, and miR-203 as a result of narrow-band UV-B phototherapy [ 56 , 57 ]. Cumulatively, this demonstrates that not only do miRNAs become differentially regulated as a result skin diseases, but also in response to the treatments applied to combat these conditions.…”

Section: Introductionmentioning

confidence: 77%

Advances in the Application and Impact of MicroRNAs as Therapies for Skin Disease

Lawrence¹,

Ceccoli²

2017

BioDrugs

View full text Add to dashboard Cite

The advent of RNA interference (RNAi) technology has profoundly impacted molecular biology research and medicine but has also advanced the field of skin care. Both effector molecules of RNAi, short-interfering RNA molecules and microRNAs (miRNAs), have been explored for their relative impact and utility for treating a variety of skin conditions. These post-transcriptional RNA regulatory molecules down-modulate protein expression through targeting of the 3′ untranslated regions of messenger RNAs, leading to their degradation or repression through sequestration. As researchers hunt for genetic linkages to skin diseases, miRNA regulators have emerged as key players in the biology of keratinocytes, fibroblasts, melanocytes, and other cells of the skin. Herein, we attempt to coalesce the current efforts to combat various skin disorders and diseases through the development of miRNA-based technologies.

show abstract

Effect of Narrow-Band Ultraviolet B Phototherapy and Methotrexate on MicroRNA (146a) Levels in Blood of Psoriatic Patients

Cited by 16 publications

References 26 publications

Deregulation of microRNA expression in monocytes and CD4+ T lymphocytes from patients with axial spondyloarthritis

Deregulation of microRNA expression in monocytes and CD4+ T lymphocytes from patients with axial spondyloarthritis

MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis

Advances in the Application and Impact of MicroRNAs as Therapies for Skin Disease

Contact Info

Product

Resources

About